MDXH
MDxHealth SA Healthcare Diagnostics & Research
8/12
Innovation Score
Patent Activity
0/3
No patents found in USPTO database (last 2026-05-11 02:16).
Cash Runway
3/3
160 months of cash remaining based on current burn rate.
Cash on hand: $29.1M
Cash on hand: $29.1M
Revenue Trajectory
2/3
Revenue: $107.9M
YoY Growth: +19.4%
YoY Growth: +19.4%
Management Quality
3/3
Insider ownership: 30.5%
SBC/Revenue: 29.0%
No reverse splits detected
SBC/Revenue: 29.0%
No reverse splits detected
Key Metrics
Market Cap
$102.7M
Revenue
$107.9M
Revenue Growth (YoY)
+19.4%
Cash on Hand
$29.1M
Cash Runway
160 months
Shares Outstanding
51.4M
Insider Ownership
30.5%
SBC / Revenue
29.0%
Sector / Industry
Healthcare / Diagnostics & Research
7-Step Risk Assessment
How MDXH maps to our micro cap methodology:
- Innovation Signal No patents found. Innovation may be trade-secret-based or too early for filings.
- Cash Runway Check 160 months of runway. Comfortable buffer for execution.
- Revenue Trajectory +19.4% YoY growth on $107.9M revenue. Positive but moderate growth.
- Management Alignment Insiders hold 30.5% of shares. SBC is 29.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $102.7M company.
Financial Detail
Free Cash Flow
$-3.7M
FCF Yield
-3.6%
Return on Equity
-2440.4%
Debt / Equity
N/A
Gross Margin
64.5%
Profit Margin
-31.1%
Operating Margin
-17.8%
Price / Book
-8.51
Current Ratio
1.08
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-11